【作者】 陶岚；

【导师】 陈锐深；

【作者基本信息】 广州中医药大学 ， 中西医结合临床， 2005， 硕士

【摘要】 第一章 文献综述与立论依据 论述了现代医学对于原发性肝癌的研究状况、祖国医学对原发性肝癌的研究分析以及本项研究的立论依据与研究意义。 第二章 临床研究 目的:观察喘可治注射液治疗中晚期原发性肝癌的疗效。 方法:将54例中晚期原发性肝癌患者随机分为治疗组(喘可治组)和对照组(华蟾素组),其中治疗组病例34例,对照组病例20例,各组均治疗1个疗程(3周),比较治疗组和对照组临床症状、瘤体大小、生存质量、体重、血分析、肝肾功能、免疫功能等。 结果:在乏力、纳呆等症状缓解方面,喘可治组明显优于华蟾素组(P<0.05、P<0.01);而在发热、肝痛、腹胀等症状缓解方面,喘可治组与华蟾素组无统计学意义(P>0.05),可以认为喘可治注射液能够在一定程度上缓解中晚期原发性肝癌患者的部分临床症状。喘可治组在治疗后癌灶稳定率达82.4%,较华蟾素组70%高,但在统计学上无统计学意义(P>0.05),说明两组都具有较好的稳定瘤体的作用,喘可治组略优于华蟾素组。通过对比两组治疗前后血常规,肝肾功能等,得出喘可治组在保护肝功能等方面与华蟾素对比有统计学意义(P<0.05),喘可治组在这方面优于华蟾素组。喘可治组在治疗后靛氰绿滞留率(ICG)方面较华蟾素组有统计学意义(P<0.05),说明喘可治注射液具有较好的改善肝癌肝脏储备功能的作用。喘可治组在治疗后增强机体细胞免疫方面如自然杀伤细胞(NKC),淋巴细胞转换率(LBT),T淋巴细胞亚群(OKT)等方面均与华蟾素组有显著性差异(P<0.01、P<0.05),表明喘可治在临床可有效地提高肝癌患者的免疫功能。另外在生存质量评分与患者体重增加上,喘可治组均与华蟾素组有显著性差异(P<0.01、P<0.05),在临床中,喘可治组未见任何毒副反应的发生。 结论:喘可治注射液能够缓解中晚期原发灶肝癌患者临床症状,改善患者生存质量,增加体重,稳定瘤体,提高免疫力等方面与华蟾素相比,具有更好的治疗效果。更多还原

【Abstract】 Part I Literature Review and StudyWe studied the knowledge of Modern Medicine and Traditional Chinese Medicine(TCM) to Primary Liver cancer Then We discussed the basic and significance of the research. Part II Clinical StudyObjective:To obsever the therapeutic efficacy of Chuankezhi Injection in treating medium or late stage Primary Liver cancer.,Methods:54patients with stage II—III liver cancer were divided randomly into two groups. In Group A(as a treated group),34 patients were treated with Chuankezhi Injection alone.In Group B(as a control group), 20 patients were Huachansu Injection alone.The therapeutic efficancy of the two groups were evaluated after one course of treatment.Results:The Group A had a better effect in the remission of symptoms such as fatigue, anorexia than. Group B (P<0. 05 or P<0. 01) there was no significant difference between Group A and Group B in the remission of symptoms such as pyrexia, ache in liver, meteorism (P>0. 05) . The complete and partial remission rate of Group A was lower than that of Group B, But no significance in statistics (P>0. 05) , Chuankezhi Injection could increase the percentage of NKC , LBT and CD3~+, CD4~+, CD4~+/CD8~+ in T-lymphocyte subcategory statistically while the percentage of NKC , LBT and CD3~+, CD4~+ , CD47~+/CD8~+ in T-lymphocyte subcategory in Group B was not significant. Chuankezhi Injection could discrease the percentage of CD8~+ in T-lymphocyte subcategory ststistically while the percentage of CD8~+ in T-lymphocyte subcategory in Group B was not significant. Group A had a better effect of raising the quality of life and weight than Group B (P<0. 05) ,The Chuankezhi Injection had no severe adverse reaction. Conclusion: The Chuankezhi Injection could alleviate symptoms, improve the更多还原